Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 490 of 5804
-
New hope for leukemia patients: asciminib shows promise in indian study
Disease control CompletedThe Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug surovatamig enters phase 2 trial
Disease control Recruiting nowThis is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Silent artery disease exposed: 16,000-Person study aims to predict heart attacks before they happen
Knowledge-focused OngoingAtherosclerosis is preventable, yet it continues to significantly contribute to global morbidity and mortality. Atherosclerosis may occur early in life and may present in all vascular territories. The DETECT study's main aim is to determine the prevalence of asymptomatic atherosc…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug combo targets tumors after hormone therapy fails
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for lung cancer patients: experimental drug takes on standard therapy
Disease control Recruiting nowThe purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumor…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New lung cancer drug aims to outperform current standard in advanced ROS1-positive patients
Disease control Recruiting nowThis is a Phase 3, randomized, open-label, comparative, multicenter, international study for NSCLC patients whose tumor tissue exhibits ROS1 fusion positivity (i.e., ROS1+) and who have not previously received an ROS1-targeted TKI (i.e., ROS1-TKI-naïve). Approximately 194 ROS-1 …
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New PET scan agent could spot kidney cancer more accurately
Diagnosis Recruiting nowThe aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal ce…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New brain drain device could help older adults walk better
Disease control OngoingProspective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Phase: NA • Sponsor: CereVasc Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Weight-Loss drug may wipe out hidden breast cancer cells
Disease control Recruiting nowThis trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweigh…
Phase: PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (castration-resistant) and that has spread…
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Virus therapy takes on deadly brain cancer
Disease control ENROLLING_BY_INVITATIONThis study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients w…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for tough AML: targeted pill plus chemo combo tested
Disease control Recruiting nowThis multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hyp…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThe goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a Copper-Lowering drug help stop Triple-Negative breast cancer recurrence?
Disease control Recruiting nowThere are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breas…
Phase: PHASE1, PHASE2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a Heart-Lung machine in an ambulance save more cardiac arrest victims?
Disease control Recruiting nowThis is a single Center interventional study, assessing the feasibility of a complex treatment strategy where an in-hospital standard care process is applied in an out-of-hospital cardiac arrest. The objective of this study is to investigate the feasibility of a prehospital eCPR…
Phase: NA • Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Disease control
Last updated Jun 26, 2026 13:36 UTC
-
New baby vaccine aims to beat pneumonia: VAX-31 trial underway
⭐️ VACCINE ⭐️ OngoingThe objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study wil…
Phase: PHASE2 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to save kidneys in rare bladder cancer
Disease control Recruiting nowThis trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC), preferring to forego standard of care radical nephr…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy drug nivolumab takes on rare childhood cancer
Disease control Recruiting nowInvestigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New mRNA HIV vaccine trial aims to train immune system to fight virus
⭐️ VACCINE ⭐️ OngoingThis is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred t…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC